UBS Raises DaVita Target to $190, Cites Elevated 2026 EPS Outlook
UBS increased its price objective for DaVita to $190 from $186 and kept a Buy rating after the company provided 2026 guidance showing robust adjusted EPS growth at the midpoint. Recent quarterly results beat expectations and management activity, including share repurchases and a planned strategic investment, are cited as contributors to near-term e…